Everest Organics Ltd
₹ 131
-0.87%
25 Apr
- close price
- Market Cap ₹ 105 Cr.
- Current Price ₹ 131
- High / Low ₹ 162 / 97.0
- Stock P/E 523
- Book Value ₹ 57.5
- Dividend Yield 0.00 %
- ROCE 3.66 %
- ROE -0.17 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.3% over past five years.
- Company has a low return on equity of 11.1% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 152 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
61 | 80 | 96 | 106 | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 195 | |
55 | 74 | 91 | 98 | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 185 | |
Operating Profit | 6 | 5 | 5 | 8 | 6 | 6 | 7 | 18 | 19 | 23 | 6 | 1 | 10 |
OPM % | 9% | 7% | 6% | 7% | 6% | 6% | 6% | 11% | 12% | 13% | 3% | 1% | 5% |
0 | 0 | 1 | -0 | -0 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 1 | |
Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 |
Depreciation | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 5 |
Profit before tax | 1 | 1 | 1 | 2 | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 |
Tax % | 22% | 22% | 21% | 20% | 18% | 24% | 28% | 39% | 23% | 21% | 34% | 311% | |
1 | 1 | 1 | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | -0 | 0 | |
EPS in Rs | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.15 | 1.42 | -0.22 | 0.25 | ||||
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 11% | 7% | 9% | 35% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 3% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -107% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -9% |
3 Years: | -27% |
1 Year: | 27% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 18% |
3 Years: | 11% |
Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9 | 9 | 9 | 9 | 3 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | -6 | -5 | -5 | -3 | 3 | 8 | 11 | 18 | 26 | 39 | 39 | 38 | 38 |
19 | 19 | 26 | 24 | 28 | 19 | 22 | 21 | 18 | 23 | 39 | 51 | 52 | |
30 | 33 | 35 | 37 | 42 | 51 | 54 | 60 | 68 | 66 | 92 | 105 | 122 | |
Total Liabilities | 52 | 56 | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 220 |
20 | 22 | 24 | 24 | 27 | 33 | 34 | 38 | 39 | 44 | 49 | 54 | 56 | |
CWIP | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 | 12 | 14 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
31 | 33 | 41 | 42 | 47 | 52 | 60 | 68 | 80 | 92 | 121 | 136 | 151 | |
Total Assets | 52 | 56 | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 220 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 0 | 1 | 4 | 7 | 10 | 5 | 9 | 10 | 14 | 14 | 18 | |
-5 | 0 | -3 | -3 | -7 | -8 | -4 | -5 | -6 | -12 | -17 | -16 | |
-2 | 0 | 2 | -2 | -0 | -2 | -1 | -3 | -3 | -2 | 2 | -3 | |
Net Cash Flow | -0 | 0 | 0 | -0 | 0 | 0 | -0 | 1 | 0 | -0 | -1 | 0 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 111 | 91 | 106 | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 |
Inventory Days | 89 | 55 | 46 | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 |
Days Payable | 200 | 164 | 184 | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 |
Cash Conversion Cycle | -0 | -18 | -32 | -40 | -63 | -83 | -55 | -24 | -12 | 29 | 24 | 9 |
Working Capital Days | -18 | -22 | 8 | 7 | 6 | -15 | 7 | 18 | 30 | 55 | 59 | 67 |
ROCE % | 17% | 15% | 13% | 19% | 11% | 13% | 13% | 35% | 35% | 34% | 6% | 4% |
Documents
Announcements
- Compliance Certificate As Per Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended 31.03.2024 2d
- Compliance Certificate Under Reg 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended On 31St March, 2024 2d
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Apr
- Closure of Trading Window 29 Mar
- Announcement under Regulation 30 (LODR)-Newspaper Publication 10 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Jul 2020TranscriptNotesPPT
Product Profile:
a) APIs:[1]
Company has products for Gastroenterology, Hypercholesterolemia, Benign Prostatic, Anti Convulsant, Hypertrophy, Hyperuricemia
and Gout, Anti Thrombotic, Anti Fungal,
Anti Viral, Anti Emetics, Anti Diabetic,
Insomnia, Skeletal muscle relaxant,
Overactive Bladder, Rhino-Conjunctivitis,
etc.
b) Intermediates:[2]
Febuxostat, Ilaprazole, Imatinib, Oseltamivir Phosphate, Abiraterone Acetate, Rivaroxaban, Itraconazole, Omeprazole, Pantoprazole, Rabeprazole, Esomeprazole, Pemetrexed, Pregabalin, Hydroxy, Chloro compound,
Sulphide, Pyrazine, Gancyclovir, Apixaban, Aprepitant, Bilastine, etc.
c) By Products:[2]
Ammonium Sulphate, Sodium Nitrite, Di
Sodium Orthophosphate, Di Ammonium
Phosphate